Inhibition of Endosomal/Lysosomal Degradation Increases the Infectivity of Human Immunodeficiency Virus
Open Access
- 15 November 2002
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (22) , 11440-11446
- https://doi.org/10.1128/jvi.76.22.11440-11446.2002
Abstract
Productive entry of human immunodeficiency virus type 1 (HIV-1) into a host cell is believed to proceed via fusion of the viral envelope with the host cell9s plasma membrane. Interestingly, the majority of HIV-1 particles that bind to the cell surface are taken up by the host cell via endocytosis; however, this mode of internalization generally does not result in infection. Presumably, virus particles remain trapped in the endocytic pathway and are eventually degraded. Here, we demonstrate that treatment of cells with various pharmacological agents known to elevate the pH of endosomes and lysosomes allows HIV-1 to efficiently enter and infect the host cell. Pretreatment of cells with bafilomycin A1 results in up to a 50-fold increase in the infectivity of HIV-1SF2. Similarly, pretreatment of target cells with amantadine, concanamycin A, concanamycin B, chloroquine, and ammonium chloride resulted in increases in HIV-1 infectivity ranging between 2- and 15-fold. Analysis of receptor and coreceptor expression, HIV-long terminal repeat (LTR) transactivation, and transduction with amphotropic-pseudotyped murine leukemia virus (MLV)-based vectors suggests that the increase in infectivity is not artifactual. The increased infectivity under these conditions appears to be due to the ability of HIV-1 and MLV particles to enter via the endocytic pathway when spared from degradation in the late endosomes and lysosomes. These results could have significant implications for the administration of current and future lysosmotropic agents to patients with HIV disease.Keywords
This publication has 56 references indexed in Scilit:
- Malaria Chemoprophylaxis in the Age of Drug Resistance. I. Currently Recommended Drug RegimensClinical Infectious Diseases, 2001
- Pharmacological treatment of Parkinson’s diseasePostgraduate Medical Journal, 2000
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- Clinical Pharmacokinetics and Metabolism of ChloroquineClinical Pharmacokinetics, 1996
- The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis.British Journal of Clinical Pharmacology, 1995
- Retrovirus-Mediated Transfer and Long-Term Expression of HIV Type 1tatGene in Murine Hematopoietic TissuesAIDS Research and Human Retroviruses, 1994
- Retrovirus Vector-Mediated Transfer of Functional HIV-1 Regulatory GenesAIDS Research and Human Retroviruses, 1994
- Chloroquine poisoning in a childAnnals of Emergency Medicine, 1990
- Clinical Pharmacokinetics of Amantadine HydrochlorideClinical Pharmacokinetics, 1988
- Fusion mutants of the influenza virus hemagglutinin glycoproteinCell, 1985